Barcelona, Spain

Ines Carranco Moruno

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.2

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2010-2016

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ines Carranco Moruno: Innovator in Pharmaceutical Chemistry

Introduction

Ines Carranco Moruno is a prominent inventor based in Barcelona, Spain. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of two patents to her name, her work focuses on innovative solutions for respiratory therapies.

Latest Patents

Ines Carranco Moruno's latest patents include the development of cyclohexyl and quinuclidinyl carbamate derivatives that exhibit β2 adrenergic agonist and M3 muscarinic antagonist activity. This invention relates to novel compounds that possess dual activity, which can be utilized in pharmaceutical compositions for respiratory therapies. Additionally, she has disclosed imidazopyridine derivatives that offer a method for treating conditions that can be improved through the antagonism of the adenosine receptor.

Career Highlights

Throughout her career, Ines has worked with notable companies such as Laboratorios Almirall, S.A. and Almirall, S.A. Her experience in these organizations has allowed her to refine her expertise in pharmaceutical research and development.

Collaborations

Ines has collaborated with esteemed colleagues, including Silvia Fonquerna Pou and Jose Aiguade Bosch. These partnerships have contributed to her innovative research and the successful development of her patents.

Conclusion

Ines Carranco Moruno stands out as a dedicated inventor in the pharmaceutical industry, with her innovative patents paving the way for advancements in respiratory therapies. Her contributions reflect her commitment to improving health outcomes through scientific innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…